Background: The lower respiratory tract infections remained the deadliest communicable disease worldwide. The relationship between cardiovascular diseases and viral infections is well known, namely myocarditis. AH1N1 influenza pandemic showed an association with developing acute cardiovascular disease, including ischemic events. Besides, the new pandemic of SARS-CoV2 became a new challenge for cardiovascular health. In early reports showed cardiac damage in patients infected with SARS-CoV2. This study aimed to describe the clinical characteristics with an emphasis on cardiovascular compromises of COVID-19 patients. Moreover, to compare with outbreaks of influenza AH1N1 to identify prognostic factors of severity. Methods: A cross-sectional study, 72 subjects with a confirmed diagnosis of COVID-19 was included, Subjects were evaluated in two groups; those hospitalized and those who required Intensive Care Unite (ICU). The data from different AH1N1 outbreaks were obtained from Velazquez et al. Results: Thirty-four subjects were admitted to ICU. Subjects at ICU, have greater levels of high sensible troponin, D dimer, creatinine, and leukocytes, than hospitalized subjects. The lymphocytes count where diminished in 85.29% of ICU subjects. SARS-CoV2 disease patients were more than one-decade older than patients in the influenza outbreaks. In SARS-CoV2 subjects the overweight and obesity proportion is half than in the influenza outbreaks; there is a big proportion, more than 6 times, of diabetes mellitus in SARS-CoV2 subjects. Conclusions: Viral respiratory infection disease as SARS-CoV2 is a significant risk factor for acute ischemic, functional, and structural cardiovascular complications.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.